November 22, 2016

 

Arm & Hammer highlights latest trial results at EuroTier 2016

 

At a research update and product training session during EuroTier 2016, Arm & Hammer highlighted its latest trial results for its yeast product CELMANAXTM, among other products.

 

As presented by Dr. Elliot Block, research fellow at Arm & Hammer, trials conducted in breeders and broilers saw 'elimination' of Salmonella and E. coli, while trials in layers saw a reduction of contamination of those bacteria in eggs.

 

For swine, several non-conclusive trials in improvements in FCR and body weight gain were reported.

 

For beef and dairy cattle, trial results were generally conclusive, with reduced cases of HBS (Haemorrhagic Bowel Syndrome, a disease with a yet unknown cause) seen.

 

Interestingly, Dr. Block pointed out that while CELMANAX does not bind DON, a mycotoxin, the product was effective in reducing cell damage (Cytotoxicity Index) caused by DON. CELMANAX was also effective against the mycotoxins ZEAR, T-2 and FUM B1. Further research would be conducted to determine the exact mechanism or mechanisms which CELMANAX uses to work against those mycotoxins.